Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cryoport (CYRX) Research & Development (2016 - 2025)

Cryoport (CYRX) has disclosed Research & Development for 14 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 7.48% to $4.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.0 million, a 3.78% decrease, with the full-year FY2025 number at $17.0 million, down 3.78% from a year prior.
  • Research & Development was $4.5 million for Q4 2025 at Cryoport, down from $4.5 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $5.2 million in Q3 2023 to a low of $3.5 million in Q2 2022.
  • A 5-year average of $4.3 million and a median of $4.2 million in 2021 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 148.36% in 2021, then decreased 21.07% in 2022.
  • Cryoport's Research & Development stood at $3.9 million in 2021, then rose by 20.23% to $4.7 million in 2022, then rose by 1.54% to $4.7 million in 2023, then fell by 12.51% to $4.2 million in 2024, then increased by 7.48% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for CYRX's Research & Development are $4.5 million (Q4 2025), $4.5 million (Q3 2025), and $4.1 million (Q2 2025).